Floatz logo

Apixaban

Venous Thromboembolism

Regeneron PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Venous Thromboembolism cohort.

Asset / SponsorPhaseRating
WARFARIN
Northern Jiangsu People's Hospital
Phase 4A
Apixaban
Northern Jiangsu People's Hospital
Phase 4BBB
Acetylsalicylic Acid
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4BBB
NADROPARIN
Rijnstate Hospital
Phase 4BBB
Rivaroxaban
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BBB

View all 35 →

Same molecule, other indications

Apixaban is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →
transient ischemic attackDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →